Latvia and Lithuania to resume use of AstraZenecas vaccines

The European Drug Agency has said on Thursday it is convinced that the benefits from AstraZenecas vaccine exceed the risks, following an investigation conducted about the blood transmission reports of some patients who have received this vaccine.

News of the vaccine's effect and security has been released by European Drug Agency Director Emer Cooke, after a long meeting at the Risk Rat Rating Commission, operating within this agency.

According to the announcement, national experts from member states also attended the meeting.

She has said that it should not be forgotten that thousands of people a day are dying in Europe as a result of COVIED-19 disease, which causes coronarys, and that vaccination is a necessary way to win the battle with pandemic.

The World Health Organisation has called on Thursday for continuing use of the vaccine.

WHO itself is expected to publish its own security research results Friday.

Although Kosovo continues to remain the only country in Europe that has not started the vaccine process, this country is expected to initially be supplied with these vaccines.

The World Health Organization scheme, COVOX, through which the coronary vaccines are expected to be distributed in poor countries, has revealed that Kosovo can be supplied with this vaccine by May.

In delivery through COVAX, Kosovo will benefit 100,800 doses of vaccine produced by the AstraZeneca company. /rel